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Abstract
Objective  Familial  hypercholesterolemia  (FH)  is  an  auto-
somal dominant inherited disorder caused by mutations in 
the  low  density  lipoprotein  receptor  (LDLR)  gene.  FH  is 
characterized by elevated plasma LDL cholesterol, prema-
ture atherosclerosis, and a high risk of premature myocar-





tion;  and  class V  defect:  no  LDLR  recycling. One might 
expect  that  both  the  class  of LDLR defect  as well  as  the 
precise mutation  influences  the  severity  of  hypercholeste-
rolemia  on  one  hand  and  the  response  on  drug  treatment 
on  the  other.  To  clarify  this  question  we  studied  the  ef-
fect of  the LDLR mutation p.W556R in  two heterozygote 
subjects.






FH patients,  in  the mean  time undergoing LDL apheresis, 
had  no  response  to  statin  but  a  15% LDL cholesterol  de-
crease on ezetimibe monotherapy.






ard  lipid-lowering  therapy,  illustrating  that  the knowledge 







uptake of  low density  lipoprotein  (LDL) and accounts  for 
the  clearance  of  70%  of  all  plasma-circulating  LDL  [1]. 





rally  used  for  LDLR  deficiency  which  is  inherited  as  an 
autosomal dominant trait. Homozygous LDLR deficiency is 
rare, with a frequency of 1 per million in the general popu-
lation  [4, 5].  It  is characterized by severely elevated LDL 



























tis  and  coronary  artery  stenosis,  and  aortic  valve  stenosis 
that  develop  in  the  first  decade  of  life,  leading  to  prema-
ture  death  from  stroke  or  myocardial  infarction  in  child-






single  nucleotide  substitutions  to  extended  deletions  had 
been identified in different ethnic groups [9–11].
According  to  the  nature  and  location  of  the mutations 
within  the  LDLR  gene,  five  different  classes  of  FH-cau-
sing mutations have been defined. Class I mutations include 
null alleles with no detectable LDL receptor protein. Class 
II  mutations  produce  transport-defective  LDLR  proteins 
that  are  either  completely  (class  II  a) or partially blocked 
(class II b or leaky LDLRs) in their transport from the endo-
plasmic  reticulum  to  the Golgi  apparatus due  to  impaired 
glycosylation [12]. Class III mutations encode LDL recep-
tors with normal  intracellular  transport but defective LDL 
















measured  after  the  precipitation  of  apoB-containing  lipo-
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Note: only normal functioning LDLR appear
at the cell surface (at a lesser degree)
Het. Class I or II defect in FH


















in  a  Protean  II  electrophoresis  system  (Bio-Rad, Munich, 
Germany).  PCR  products  of  LDLR  exons  with  aberrant 
DGGE  patterns  were  sequenced  in  forward  and  reverse 
directions with  the BigDyeTM  terminator cycle sequencing 
ready  reaction  kit  (Applied Biosystems, Warrington, UK) 
on an ABI 3730 DNA sequencer.
Results
The  index  family  is  a  Turkish  family  with  two  identi-
cal  male  twins,  who  are  homozygote  for  the  p.W556R 
LDLR mutation.  Their  parents  are  both  heterozygote  for 
the p.W556R LDLR defect. The ApoE phenotype was 3/3 
and  by  this  normal  in  all  patients. At  the  age  of  2  years, 
the  twins showed multiple  tuberoeruptive xanthomas over 
the  extensor  surface  of  the  elbows,  knees,  subcutaneous 




LDL  cholesterol  above  25.8 mmol/L  (> 1000 mg/dL).  By 
this the twins meet the diagnostic criteria for homozygous 
FH which was confirmed by identifying the primary LDLR 
defect  [17].  The  boys  were  initially  treated  with  statins, 
however,  there was no measureable decrease in LDL cho-
lesterol (< 5%). Interestingly,  the treatment with ezetimibe 






signs  for  coronary  artery  disease  (CAD);  however,  there 
was a strong family history of CAD. The male subject had 
untreated a total cholesterol of 9.8 mmol/L (= 379 mg/dL) 
and LDL  cholesterol  of  7.7 mmol/L  (= 298 mg/dL), whe-
reas the female subject with the identical genetic defect had 
initially  a  total  cholesterol  of  7.6 mmol/L  (= 296 mg/dL) 







We  identified  the molecular  basis  of  LDLR  deficiency  in 


















In  FH,  two  thirds  of  all  known  mutations  are  located 






Patients Sex Age (years) TC (mmol/L) TG (mmol/L) LDL-C (mmol/L) HDL-C (mmol/L) LDLR (p.W556R)
No lipid-lowering therapy M 36 9.8 1.7 7.7 1.2 Heteroz
Simvastatin 40 mg/ezetimibe 10 mg 5.2 1.1 3.5 1.1
No lipid-lowering therapy F 30 7.6 1.3 5.2 1.8 Heteroz


















ding  is  of  special  interest  since  both  subjects  have  the 
identical genetic defect leading to FH; however, simply 
the gender seems to influence the LDL cholesterol levels 





2.   The  LDL  cholesterol-lowering  potency  of  simvastatin 
40 mg/ezetimibe 10 mg was impressive in both subjects. 









This  underlines  the  heterogeneity  in  hyperlipidemic 
patients  and  the  need  of  appropriate  knowledge  of  the 
primary defects.
The  rather  strong  LDL-lowering  effect  of  simvastatin 
40  mg/ezetimibe  10  mg  in  both  heterozygote  subjects  is 
remarkable,  even more  so  since  the  homozygote  children 





whereas  simvastatin  40  mg/ezetimibe  10  mg  provides  a 
decrease in LDL cholesterol of − 55%.





we have a defect resulting  in  the  lack of LDLR transport. 
In the homozygote state we see no LDLR at all on the cell 
surface, making  this  defect  to be one of  the worst LDLR 
mutations known so far. However, in the heterozygote state 
we  see  only  fully  functional  LDLR’s  on  the  cell  surface, 
since  the  LDLR  defect  is  not  coming  through  the  LDLR 
pathway (see Fig. 1b). Once the LDLR system is stimulated 
by statin  treatment we expect  to see more  (and only  fully 





on  the  location of  the mutation)  increase LDL cholesterol 
more  or  less  severely.  However,  in  its  heterozygote  state 
we will  see—different  from  class  I  or  II  defects—always 
a mixture  of  functional  and  non  functional  LDLR  on  the 
cell surface. This mixture of functional and non functional 
LDLR  will  increase  under  statin  therapy.  Different  from 
heterozygote LDLR class  I or  II mutations,  the non  func-
tional LDLR class  III  or  IV will  compete with  functional 
LDLR on the cell surface and by this interact with an appro-

















In  the near  future,  thanks  to  the worldwide  efforts  and 
upcoming screening procedures, we should be able to pre-
dict  the  potential  and  benefit  of  any  given  lipid-lowering 
drug  and  the  need  of  LDL  apheresis,  once  we  know  the 
precise genetic defects leading to hypercholesterolemia and 
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